H2020Индивидуална стипендия2021–2023

MicroMI · Factors driving mother-to-infant microbiota transfer

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-08-31
Финансиране от ЕС: 172 932 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Преносът на микробиоти от майката към бебето през първия месец, като например предаването на бактерии от рода Bifidobacterium, определя състава на чревната флора. Това помага за разбирането на развитието на имунната система и метаболизма, за да се намали рискът от алергии и затлъстяване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Factors driving mother-to-infant microbiota transfer

MicroMI aimed to investigate the mother-to-infant transfer of microbiota during the first month of life and its role in infant’s gut microbiota composition and functionality and the consequences in infant’s development. The gut microbiota, which is a complex community of microorganisms (bacteria, virus, fungi), that inhabit in our gut, have key functions in our body, including the development of the immune system, metabolism and maturation of the gastrointestinal tract (GIT). The establishment of the gut microbiota starts at birth and develops over time coinciding with the maturation of the GIT and immune system. Infant gut microbiota alterations have been linked to higher risk of noncommunicable diseases (NCDs) as allergy, obesity and cardiovascular diseases. NCDs are increasing and account for more than 41 million people deaths per year (71% of all deaths globally), being more critical in infants. Thus, early microbial colonization is essential for an optimal health. The mother is the main source of microbiota to the infant, representing a pivotal step in the development of infant gut microbiota. The study of the microbiota from mother-infant is key for understanding the function of these pioneering bacteria in the infant gut development. The data from MicroMI showed exciting ground-breaking results by performing state-of-the-art research. This project revealed that Bifidobacterium strains are highly isolated from mother-infant pairs and they showed more potential transference events than other microbial groups. The isolation of these strains allowed an in-depth understanding of the functionality and probiotic properties of these bacteria in the infant gut and the cross-talking with the host. Thus, MicroMi has originated a collection of Bifidobacterium strains genetically and functionally characterized with high value for the development of next-generation probiotics with known mechanisms of action. These strains can be used as new dietary interventions to treat or prevent a range of disorders and improve public health.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Human microbiota has vital effects on human health and physiology. Gut microbiota alteration has been linked to risk of non-communicable diseases (NCDs) as allergy, obesity and cardiovascular diseases. NCDs are increasing and account for more than 41 million people deaths per year (71% of all deaths globally), being more critical in infants. Early microbial colonization of the GIT is essential for an optimal health, thus, altered microbial colonization patterns have been linked to an increased risk of NCDs. Mother-to-infant transfer of microbes is believed to be a crucial opportunity to pass on IM from one generation to another, representing a pivotal step in the development of the early infant gut microbiota. Much research to date has addressed the impact of the environment on the microbiota composition, nowadays, is time to go further and to define this mechanism in a compositional, functional and metabolic level. An in-depth understanding of the effect of maternal IM in the early life and its long-term impact is urgently needed. The EU is promoting actions developing new dietary solutions to improve public health, therefore, MicroMI aims to make a novel approach by using state-of-the-art methodologies already established within the host institution (CSIC) to reveal the mechanisms underlying this host-microbe interaction in the GIT development and maturation in early life. MicroMI adapts methods based on cutting-edge sequencing technologies to gain knowledge on probiotic-related issues. This project will positively impact on the European society and economy. Within MicroMi, the applicant will perform state-of-the-art research, will promote science as a career and gender equality and she will establish an innovative translation multidisciplinary programme. Funding of this action will allow the research applicant to foster and share her skills and reinforce herself as a mature and independent professional, starting to forge a stable career.

Оригинален текст от CORDIS (на английски).

Участници

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS · MadridКоординаторИспания